I've just added the latest ITP lifespan data from the 2024 ITP study (pubmed: 38753230) to the Longevity Intervention Database (LID). There were no findings on new maximum lifespan extending compounds. But one new compound, 16-a-hydroxyestriol, extended median lifespan in male

Last year during the ARDD 2024 conference the researcher Nir Barzilai presented an updated version of a ranked list of compounds with longevity potential. One purpose of the list is to help to guide the research efforts and financial investments in the field. One thing to keep in

In my previous post I lifted up an interesting ranked list of compounds with longevity potential that the researcher Nir Barzilai presented at the ARDD 2024 conference. Now I would like to share another very interesting overview which he presented at the conference around

One good place to start is by stating that biological clocks are far from perfect but there are many efforts in the field to try to improve and develop clocks that will be even better than the ones we have today. One important goal is to develop a good biological clock that could

Big thanks Raghav "RV" Sehgal for highlighting this research on rapamycin and its implications for longevity medicine. The researcher Girish did a great work here. I’m honored to have been part of this study, which emphasizes the importance of personalized dosing and monitoring

Alejandro Ocampo, Kevin Perez and other researchers published earlier this year lots of interesting lifespan data in roundworms and fruit flies (pubmed: 39853804). I have now imported this data to the Longevity Intervention Database. In the below image you can see a list of the

Exciting news! $50 000 is now secured, which means that the first subproject is fully funded around the largest mTOR screening project that has ever been done! So Ora Biomedical, Inc. can now begin the wormbot screening of the first 301 mTOR inhibitors out of the 601 in the full

Congratulations to Ora Biomedical, Inc. on fully funding subproject one - the first phase in a project that seeks out next-gen therapies more effective than rapamycin. Learn more and contribute: lifespan.io/news/the-mtor-… Krister Kauppi - Rapamycin Longevity Lab Mitchell B Lee, PhD keithcomito.eth Lifespan Research Institute

How can we determine which interventions are effective for specific individuals and not? This is an important question to figure out because things point towards that there is no one shoe that fits all. In this post I will present a first sketch of a visual representation of

Randomized clinical trials are the ones we want for getting high level scientific data around different potential longevity interventions. One big problem is that they are very costly. But there are quite many people in the longevity community who self-experiment with different

Levity is one of my favorite longevity podcasts and I was honored to be featured in their latest newsletter. Check it out!

Sometimes I get asked how I managed to get so much done and the answer is that I really try to strive to keep up momentum in moving things forward each day. In some cases it is just a mini todo around for example my lab initiative and in other cases it’s much bigger things. This

I’m excited to share the status of our nine active Rapamycin Longevity Lab projects! Here’s a glimpse into our current pipeline: 1️⃣ GSK2126458, also known as Omipalisib, is the molecule that started it all! Discovered by our lab last year and it showed really good lifespan

Last week, I ran a series of tests after a 3-month break from taking rapamycin. Unfortunately, I came down with the flu the very next day. That timing likely means the virus was already latent during testing, which could skew the results. So while it's disappointing, it's also a

We’re thrilled to announce that we’ve reached 28% funding for our second subproject, where we’ll screen the remaining 300 mTOR inhibitors! The goal is to uncover the next breakthrough beyond the mTOR inhibitor Rapamycin, which is currently the most promising longevity compound

Many have seen Linda Partridge paper (pubmed: 40437307) on the combination of Rapamycin and Trametinib. I remember last year during the summer when she and her research team published a preprint of this study. It was also interesting to talk with her at the ARDD 2024 conference

The Superhuman Longevity Summit in Stockholm last week was a great one! Massive thanks, Bryan Johnson, Ash Pournouri, Alexander Pärleros and everyone else who helped organize it! I also took the opportunity to say a few words at the end about longevity. It really sucks to get old,